Adults 18 to 70, any sex, with Palmoplantar Pustulosis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to BaselinePrimary· Baseline to Day 28
Relative change from baseline in fresh pustule count at Day 28
Group
Value
95% CI
RIST4721 300 mg
0.86
± 0.692
Placebo
0.53
± 0.561
Log Transformed Ratio of Postbaseline Total Pustule Count at Day 28 to BaselinePrimary· Baseline to Day 28
Relative change from baseline in total pustule count at Day 28
Group
Value
95% CI
RIST4721 300 mg
0.99
± 0.667
Placebo
0.96
± 0.672
Adverse events — posted to ClinicalTrials.gov
Time frame: From ICF signature to end of study participation (approximately 73 days).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05448391 — A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)
· Phase 2
· withdrawn
NCT05348681 — A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)
· Phase 2
· terminated
NCT05194839 — A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
· Phase 2
· terminated
NCT04105959 — A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Mod
· Phase 1
· completed
Other recruiting trials for Palmoplantar Pustulosis
Currently open trials in the same condition.
NCT07219420 — A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
· Phase 3
· recruiting
NCT07013201 — A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to
· Phase 2
· recruiting
Other Aristea Therapeutics, Inc. trials
Trials by the same sponsor.
NCT05448391 — A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)
· Phase 2
· withdrawn
NCT05348681 — A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)
· Phase 2
· terminated
NCT05194839 — A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
· Phase 2
· terminated
NCT05023811 — A Study of the ADME of [14C]RIST4721 in Healthy Male Subjects
· Phase 1
· completed
NCT04105959 — A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Mod
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aristea Therapeutics, Inc.
Last refreshed: 5 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03988335.